CUE - Cue Biopharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.27
+0.14 (+2.73%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.13
Open5.12
Bid5.10 x 900
Ask5.90 x 1400
Day's Range5.11 - 5.49
52 Week Range4.47 - 17.99
Volume94,335
Avg. Volume99,461
Market Cap106.102M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Cue Biopharma to Host Business Update Call and Webcast

    Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will host a conference call and webcast to provide a business update on November 20, 2018 at 4:30 pm ET. Live and archived versions of the event can be accessed via the Company’s website. Members of the Cue Biopharma executive management team will provide an update on the Company’s platform and pipeline progress, including a high level overview of  data presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting and the recent strategic collaboration with LG Chem Life Sciences, as well as updates on its strategic objectives and anticipated milestones.

  • GlobeNewswirelast month

    Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

    Cue Biopharma™, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to modulate antigen-specific T cells to treat cancer, autoimmune and chronic infectious diseases, announced today preclinical results demonstrating the potential of its Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and lead candidate CUE-101. The poster, entitled “CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies,” (P185) is being presented today during the poster session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting being held in Washington, D.C.

  • GlobeNewswirelast month

    Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in Oncology

    Collaboration Expands Development and Manufacturing of Immuno-STAT™ Biologics and Broadens Coverage of Patient Populations CAMBRIDGE, Mass., Nov. 08, 2018 -- Cue Biopharma™,.

  • GlobeNewswire2 months ago

    Dr. Anish Suri, Cue Biopharma’s CSO, to Present at Upcoming Precision: Lung Cancer Summit

    Cue Biopharma™, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that Anish Suri, Ph.D., Senior Vice President and Chief Scientific Officer will deliver a presentation entitled “Immuno-STATs: a novel biologic platform to enable antigen-specific immunotherapies” at the Precision: Lung Cancer Summit, on October 29 at 3:30 PM ET the Wyndham Boston Beacon Hill in Boston. Dr. Suri will present an overview and update on the Immuno-STAT™ platform, which will cover new mechanistic data from various experimental models, including human blood, demonstrating how Immuno-STATs are able to bind with specificity to the target T cell receptor, and activate and differentiate T cells into cytotoxic killer T cells.

  • Simply Wall St.2 months ago

    What Kind Of Shareholders Own Cue Biopharma Inc (NASDAQ:CUE)?

    The big shareholder groups in Cue Biopharma Inc (NASDAQ:CUE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...

  • Business Wire10 months ago

    Cue Biopharma to Present at BIO CEO & Investor Conference

    Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be presenting at the BIO CEO & Investor Conference on Tuesday, February 13, 2018, at 1:30 pm ET , at the New York Marriott Marquis Hotel, NY.

  • Business Wire11 months ago

    Cue Biopharma to Provide Corporate Update at the 10th Annual Biotech Showcase 2018 Conference

    Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be featured as a presenting company at the upcoming 10th Annual Biotech Showcase Conference™ on January 9, 2018, in San Francisco, CA.

  • Business Wire11 months ago

    Cue Biopharma Announces Closing of Initial Public Offering

    Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced the closing of its initial public offering of 8,820,710 shares of its common stock at a public offering price of $7.50 per share on December 27, 2017.